Skip to main content

ACR-ACNM-ASTRO-SNMMI Practice Parameter for the Performance of Therapy With Radium-223.

Publication ,  Journal Article
Hurwitz, M; Buscombe, JR; Jacene, HA; Klitzke, AK; Lamonica, D; Lu, Y; Pryma, DA; Rohren, EM; Speer, TW; Subramaniam, RM; Thompson, HM ...
Published in: Am J Clin Oncol
August 2020

AIM/OBJECTIVES/BACKGROUND: The goal of therapy with unsealed radiopharmaceutical sources is to provide either cure or significant prolongation of disease-specific survival, and effective reduction and/or prevention of adverse disease-related symptoms or untoward events while minimizing treatment-associated side effects and complications. Radium-223 dichloride (radium-223) is an alpha particle-emitting isotope used for targeted bone therapy. This practice parameter is intended to guide appropriately trained and licensed physicians performing therapy with radium-223. Such therapy requires close cooperation and communication between the physicians who are responsible for the clinical management of the patient and those who administer radiopharmaceutical therapy and manage the attendant side effects. Adherence to this parameter should help to maximize the efficacious use of radium-223, maintain safe conditions, and ensure compliance with applicable regulations. METHODS: This practice parameter was developed according to the process described on the American College of Radiology (ACR) website ("The Process for Developing ACR Practice Parameters and Technical Standards," www.acr.org/ClinicalResources/Practice-Parameters-and-Technical-Standards) by the Committee on Practice Parameters of the ACR Commission on Radiation Oncology in collaboration with the American College of Nuclear Medicine (ACNM), the American Society for Radiation Oncology (ASTRO), and the Society of Nuclear Medicine and Molecular Imaging (SNMMI). All these societies contributed to the development of the practice parameter and approved the final document. RESULTS: This practice parameter addresses the many factors which contribute to appropriate, safe, and effective clinical use of radium-223. Topics addressed include qualifications and responsibilities of personnel, specifications of patient examination and treatment; documentation, radiation safety, quality control/improvement, infection control, and patient education. CONCLUSIONS: This practice parameter is intended as a tool to guide clinical use of radium-223 with the goal of facilitating safe and effective medical care based on current knowledge, available resources and patient needs. The sole purpose of this document is to assist practitioners in achieving this objective.

Duke Scholars

Published In

Am J Clin Oncol

DOI

EISSN

1537-453X

Publication Date

August 2020

Volume

43

Issue

8

Start / End Page

539 / 544

Location

United States

Related Subject Headings

  • Radium
  • Radioisotopes
  • Oncology & Carcinogenesis
  • Humans
  • Combined Modality Therapy
  • Bone Neoplasms
  • Antineoplastic Agents
  • 3211 Oncology and carcinogenesis
  • 1105 Dentistry
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Hurwitz, M., Buscombe, J. R., Jacene, H. A., Klitzke, A. K., Lamonica, D., Lu, Y., … Brown, R. K. J. (2020). ACR-ACNM-ASTRO-SNMMI Practice Parameter for the Performance of Therapy With Radium-223. Am J Clin Oncol, 43(8), 539–544. https://doi.org/10.1097/COC.0000000000000702
Hurwitz, Mark, John R. Buscombe, Heather A. Jacene, Alan K. Klitzke, Dominick Lamonica, Yang Lu, Daniel A. Pryma, et al. “ACR-ACNM-ASTRO-SNMMI Practice Parameter for the Performance of Therapy With Radium-223.Am J Clin Oncol 43, no. 8 (August 2020): 539–44. https://doi.org/10.1097/COC.0000000000000702.
Hurwitz M, Buscombe JR, Jacene HA, Klitzke AK, Lamonica D, Lu Y, et al. ACR-ACNM-ASTRO-SNMMI Practice Parameter for the Performance of Therapy With Radium-223. Am J Clin Oncol. 2020 Aug;43(8):539–44.
Hurwitz, Mark, et al. “ACR-ACNM-ASTRO-SNMMI Practice Parameter for the Performance of Therapy With Radium-223.Am J Clin Oncol, vol. 43, no. 8, Aug. 2020, pp. 539–44. Pubmed, doi:10.1097/COC.0000000000000702.
Hurwitz M, Buscombe JR, Jacene HA, Klitzke AK, Lamonica D, Lu Y, Pryma DA, Rohren EM, Speer TW, Subramaniam RM, Thompson HM, Tomblyn MB, Wong WW, Xiao Y, Banks KP, Brown RKJ. ACR-ACNM-ASTRO-SNMMI Practice Parameter for the Performance of Therapy With Radium-223. Am J Clin Oncol. 2020 Aug;43(8):539–544.

Published In

Am J Clin Oncol

DOI

EISSN

1537-453X

Publication Date

August 2020

Volume

43

Issue

8

Start / End Page

539 / 544

Location

United States

Related Subject Headings

  • Radium
  • Radioisotopes
  • Oncology & Carcinogenesis
  • Humans
  • Combined Modality Therapy
  • Bone Neoplasms
  • Antineoplastic Agents
  • 3211 Oncology and carcinogenesis
  • 1105 Dentistry